Zydelig (idelalisib)

pCPA File Number: 20829

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CDA-AMC Project Number:

PC0057-000

pCPA Engagement Letter Issued:

2015-09-24

Negotiation Process Concluded:

2016-06-03